These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 31066809)

  • 1. Crohn's disease - treatment with biological medication.
    Zaltman C; Amarante H; Brenner MM; Costa MHM; Flores C; Leal RF; Grain JFS; Zeroncio M
    Rev Assoc Med Bras (1992); 2019 May; 65(4):554-567. PubMed ID: 31066809
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ulcerative colitis - treatment with biologicals.
    Teixeira FV; Vilela EG; Damião AOMC; Vieira A; Albuquerque IC; Parente JML; Chebli JMF; Ambrogini Junior O; Hossne RS; Miszputen SJ
    Rev Assoc Med Bras (1992); 2019 May; 65(4):547-553. PubMed ID: 31066808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.
    Behm BW; Bickston SJ
    Cochrane Database Syst Rev; 2008 Jan; (1):CD006893. PubMed ID: 18254120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimizing biological therapy in Crohn's disease.
    Gecse KB; Végh Z; Lakatos PL
    Expert Rev Gastroenterol Hepatol; 2016; 10(1):37-45. PubMed ID: 26471077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-Effectiveness Comparison of Ustekinumab, Infliximab, or Adalimumab for the Treatment of Moderate-Severe Crohn's Disease in Biologic-Naïve Patients.
    Aliyev ER; Hay JW; Hwang C
    Pharmacotherapy; 2019 Feb; 39(2):118-128. PubMed ID: 30565265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Crohn's disease--infliximab, adalimumab and certolizumab-pegol: clinical value of anti-TNF-alpha treatment].
    Schreiber S
    Dtsch Med Wochenschr; 2007 Aug; 132(34-35):1770-4. PubMed ID: 17713889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice.
    Gisbert JP; Chaparro M
    J Crohns Colitis; 2020 Jun; 14(5):694-709. PubMed ID: 31777929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ustekinumab is effective and safe in the treatment of Crohn's disease refractory to anti-TNFα in an orthotopic liver transplant patient.
    Martínez-Montiel M; Piedracoba-Cadahia P; Gómez-Gómez C; Gonzalo J
    J Crohns Colitis; 2015 Sep; 9(9):816-7. PubMed ID: 26071409
    [No Abstract]   [Full Text] [Related]  

  • 9. Use of Anti-Tumor Necrosis Factors and Anti-Integrins in the Treatment of Crohn's Disease.
    Shivashankar R; Pardi DS
    Gastroenterol Clin North Am; 2017 Sep; 46(3):589-601. PubMed ID: 28838417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
    Magro F; Portela F
    BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimizing Selection of Biologics in Inflammatory Bowel Disease: Development of an Online Patient Decision Aid Using Conjoint Analysis.
    Almario CV; Keller MS; Chen M; Lasch K; Ursos L; Shklovskaya J; Melmed GY; Spiegel BMR
    Am J Gastroenterol; 2018 Jan; 113(1):58-71. PubMed ID: 29206816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-tumor necrosis factor agents reduce corticosteroid use compared with azathioprine in patients with Crohn's disease.
    Kane SV; Jaganathan S; Bedenbaugh AV; Palmer L; Schwartz DA
    Curr Med Res Opin; 2014 Sep; 30(9):1821-6. PubMed ID: 24884302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Certolizumab pegol: new drug. As a last resort in Crohn's disease: continue to use other TNF alpha inhibitors.
    Prescrire Int; 2009 Jun; 18(101):108-10. PubMed ID: 19637418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of antitumour necrosis factor-α and anti-interleukin-12/23 antibodies in refractory psoriasis and psoriatic arthritis: a long-term case-series observational study.
    Gniadecki R; Bang B; Sand C
    Br J Dermatol; 2016 May; 174(5):1145-6. PubMed ID: 26522308
    [No Abstract]   [Full Text] [Related]  

  • 15. Experience With Anti-TNF-α Biologic Agents in Succession in Patients With Crohn's Disease: A Retrospective Analysis of a Single Center.
    Ferges W; Rampertab SD; Shafqet M; Salimi Q; You G; Yousefzadeh E; Cheng JQ; Das KM
    J Clin Gastroenterol; 2016 Apr; 50(4):326-30. PubMed ID: 25984976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment with anti-TNFalpha agents in Crohn's disease: what drug we have to use and when?].
    Gomollón F; López SG
    Acta Gastroenterol Latinoam; 2008 Jun; 38(2):133-45. PubMed ID: 18697408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vedolizumab and Infliximab Combination Therapy in the Treatment of Crohn's Disease.
    Hirten R; Longman RS; Bosworth BP; Steinlauf A; Scherl E
    Am J Gastroenterol; 2015 Dec; 110(12):1737-8. PubMed ID: 26673509
    [No Abstract]   [Full Text] [Related]  

  • 18. Characteristics of biological therapy in pediatric patients with Crohn's disease.
    Tarnok A; Kiss Z; Kadenczki O; Veres G
    Expert Opin Biol Ther; 2019 Mar; 19(3):181-196. PubMed ID: 30601083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What is the importance of anti-TNF agents in the treatment of luminal (inflammatory type) Crohn's disease?
    Kabaçam G; Törüner M
    Turk J Gastroenterol; 2010 Mar; 21(1):107-12. PubMed ID: 20552736
    [No Abstract]   [Full Text] [Related]  

  • 20. Maintenance therapy with certolizumab pegol for Crohn's disease.
    Schreiber S; Khaliq-Kareemi M; Lawrance IC; Thomsen OØ; Hanauer SB; McColm J; Bloomfield R; Sandborn WJ;
    N Engl J Med; 2007 Jul; 357(3):239-50. PubMed ID: 17634459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.